Vice President, Operations – Europe ; Managing Director – Velocity Clinical Research, Leipzig GmbH
Sandra Stark, PhD joined Velocity Clinical Research after 18 years at Parexel where she held various positions in Project Management, Business Development, and Portfolio Management. After leading the Therapeutic Area of Immunology and Rare Diseases in Early Phase for seven years, she took on the role of Unit Head of Parexel’s Phase 1 unit in Berlin, Germany – a 120-bed Clinical Pharmacology clinic. Moving from the Sponsor/CRO side of clinical research to Velocity Clinical Research not only closes the loop full circle, it expands her experience into late-stage development. Dr. Stark brings over 20 years of experience in both the CRO and biopharmaceutical industry, with extensive knowledge in Early Drug Development, Translational Medicine, Pre-clinical, and thorough strategic development, to her roles with Velocity, focusing on fast and efficient POC to support go/no-go decisions for late-stage development. Dr. Stark holds a Diploma in Biology from Kassel University and a PhD in Immunology and Immunogenetics from University of Göttingen.
